Pancreatic Enzyme Replacement Therapy: Drugs
The question
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with pharmaceutical manufacturers on resolving supply chain issues with pancreatic enzyme replacement therapy medications; and what his planned timetable is for the restoration of normal supply levels.
Answered by Karin Smyth
The Department is continuing to engage with all suppliers of pancreatic enzyme replacement therapy (PERT) to boost production to mitigate the supply issue. Through this work we have managed to secure additional volumes of PERT for 2025. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market. In December 2024, the Department issued further management advice to healthcare professionals. This directs clinicians to consider these unlicensed imports when licensed stock is unavailable and includes actions for integrated care boards to ensure local mitigation plans are put in place and implemented. The Department, in collaboration with NHS England, has created a webpage to include the latest update on PERT availability and easily accessible advice on the prescribing and ordering of alternative PERT products.
We expect normal supply to resume in 2026 but will remain focused on pushing manufacturers to shorten this timeline. The Department also has frequent conversations with representatives from the impacted patient groups so that they are informed on the supply situation and the mitigation actions being taken.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →